Log In
Print
BCIQ
Print
Print this Print this
 

demcizumab (OMP-21M18)

  Manage Alerts
Collapse Summary General Information
Company OncoMed Pharmaceuticals Inc.
DescriptionHumanized IgG2 mAb against delta-like 4 (DLL4)
Molecular Target Delta-like 4 (DLL4)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,277.3M

0

$3,100.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today